Department of Burns and Plastic Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China.
Department of Plastic Surgery, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi, China.
Folia Histochem Cytobiol. 2020;58(4):255-263. doi: 10.5603/FHC.a2020.0026. Epub 2020 Nov 13.
The abnormal expression of Zinc Finger Protein 750 (ZNF750) has been reported in neoplastic diseases. This study investigated the functional role of ZNF750 in the progression of melanoma.
Quantitative real-time PCR and immunohistochemistry (IHC) were performed to detect the expression levels of ZNF750 in patients diagnosed with primary cutaneous malignant melanoma. The correlation between clinical-pathological features and ZNF750 expression were clarified. Cell Counting Kit-8 (CCK-8), colony formation and transwell assays were used to explore the effects of ZNF750 on the proliferation, colony formation, migration and invasion of melanoma cells. Western blot assay was used to evaluate the effects of ZNF750 on regulating epithelial-mesenchymal transition (EMT) related proteins.
ZNF750 expression was down-regulated in human melanoma tissues and cells, and correlated with the clinical-pathological features including tumor size, lymph node metastasis, and Clark classification in patients with melanoma. In addition, overexpression of ZNF750 decreased the proliferation, invasion and suppressed EMT of melanoma cells, whereas ZNF750 depletion showed the opposite effects. Importantly, mechanistic analyses implied that upregulation of ZNF750 inhibited the expression of b-catenin and the downstream targets (cyclin D1, c-Myc, Bcl-2, MMP2 and MMP9), indicating it could block the activation of Wnt/b-catenin pathway. Consistently, knockdown of ZNF750 led to the opposite results.
Together, ZNF750 serves as a tumor suppressor for the development and progression of melanoma through regulating the Wnt/b-catenin pathway. This study confirms the involvement of ZNF750 in melanoma progression and may provide a promising therapeutic target for the treatment of melanoma.
锌指蛋白 750(ZNF750)的异常表达已在肿瘤疾病中报道。本研究探讨了 ZNF750 在黑色素瘤进展中的功能作用。
通过定量实时 PCR 和免疫组织化学(IHC)检测诊断为原发性皮肤恶性黑色素瘤患者中 ZNF750 的表达水平。阐明 ZNF750 表达与临床病理特征之间的相关性。细胞计数试剂盒-8(CCK-8)、集落形成和 Transwell 测定用于探索 ZNF750 对黑色素瘤细胞增殖、集落形成、迁移和侵袭的影响。Western blot 测定用于评估 ZNF750 对调节上皮-间充质转化(EMT)相关蛋白的影响。
ZNF750 在人黑色素瘤组织和细胞中表达下调,与黑色素瘤患者的临床病理特征(包括肿瘤大小、淋巴结转移和 Clark 分级)相关。此外,过表达 ZNF750 降低了黑色素瘤细胞的增殖、侵袭并抑制了 EMT,而 ZNF750 耗竭则显示出相反的效果。重要的是,机制分析表明,ZNF750 的上调抑制了 b-连环蛋白及其下游靶标(细胞周期蛋白 D1、c-Myc、Bcl-2、MMP2 和 MMP9)的表达,表明它可以阻断 Wnt/b-连环蛋白通路的激活。一致地,ZNF750 的敲低导致了相反的结果。
ZNF750 通过调节 Wnt/b-连环蛋白通路,作为黑色素瘤发生和发展的肿瘤抑制因子。本研究证实了 ZNF750 参与黑色素瘤的进展,并可能为黑色素瘤的治疗提供有前途的治疗靶点。